VistaGen Therapeutics, Inc. (VTGN) Shares Bought by D.A. Davidson & CO.
D.A. Davidson & CO. increased its stake in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) by 8.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 98,500 shares of the company’s stock after buying an additional 7,500 shares during the period. D.A. Davidson & CO. owned about 1.06% of VistaGen Therapeutics worth $184,000 as of its most recent SEC filing.
Shares of VistaGen Therapeutics, Inc. (NASDAQ VTGN) opened at 1.59 on Friday. VistaGen Therapeutics, Inc. has a 12-month low of $1.54 and a 12-month high of $4.45. The company’s 50-day moving average is $1.66 and its 200-day moving average is $1.85. The stock’s market cap is $14.91 million.
VistaGen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Monday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that VistaGen Therapeutics, Inc. will post ($1.99) earnings per share for the current year.
VistaGen Therapeutics Profile
VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for VistaGen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.